News

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...
Eli Lilly’s stock closed at $786.92, marking a 1.19% gain, outpacing the broader market. Despite a 3.66% drop in the past ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...
Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...
Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...
Irish-made medicines heading to the US face steep new duties, raising alarm among patients, producers and investors on both ...